Bolt Biotherapeutics Change in Accounts Payable 2020-2025 | BOLT

Bolt Biotherapeutics change in accounts payable from 2020 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Bolt Biotherapeutics Change in Accounts Payable 2020-2025 | BOLT

Bolt Biotherapeutics change in accounts payable from 2020 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.1B
Amgen (AMGN)$155.3B
Gilead Sciences (GILD)$141.6B
Vertex Pharmaceuticals (VRTX)$99.7B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$80.7B
CSL (CSLLY)$67.1B
Regeneron Pharmaceuticals (REGN)$60.7B
Alnylam Pharmaceuticals (ALNY)$58.2B
Argenex SE (ARGX)$41.5B
Insmed (INSM)$27.1B
BioNTech SE (BNTX)$25.3B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16.2B
Genmab (GMAB)$15.6B
Illumina (ILMN)$15.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.2B
Moderna (MRNA)$9.9B
Verona Pharma American Depositary Share (VRNA)$9.1B
Bio-Techne Corp (TECH)$8.9B
Exact Sciences (EXAS)$8.6B
Halozyme Therapeutics (HALO)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B